95 completed, 61 terminated, 45 active not recruiting, 26 withdrawn. 183 Phase 2, 110 Phase 1, 18 Phase 3, 6 Early Phase 1, 1 Not applicable.
Follow avelumab: new trials by email Literature Review of avelumab trials Research Report on avelumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer AlloStim, Bavencio - Metastatic Colorectal Cancer | Phase 2 | Withdrawn | Mirror Biologics, Inc. | 2026-11-01 | 2025-10-21 | |
| Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma Avelumab 800 mg flat-dose IV - Urothelial Carcinoma | Phase 2 | Not yet recruiting | Gruppo Oncologico Italiano di Ricerca Clinica | 144 | 2026-06-01 | 2026-03-10 |
| DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma Avelumab, enfortumab vedotin - Penile Squamous Cell Carcinoma (PSCC) | Phase 2 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 25 | 2025-12-16 | 2026-10-13 |
| Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC Avelumab 10 mg/kg, Screening, Best Supportive Care (BSC) - Upper Tract Urothelial Carcinoma | Phase 2 | Recruiting | Samsung Medical Center | 48 | 2025-09-16 | 2025-11-06 |
| Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) 225Ac-SSO110 + SoC, Atezolizumab, Durvalumab - Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Ariceum Therapeutics GmbH | 2 | 2025-07-01 | 2026-02-05 |
| Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer copanlisib, Avelumab - Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Withdrawn | VA Office of Research and Development | 2025-06-02 | 2025-06-15 | |
| Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19. Cetuximab/avelumab - Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer | Phase 2 | Recruiting | Gruppo Oncologico del Nord-Ovest | 67 | 2025-02-20 | 2025-03-14 |
| Avelumab and M1774 in ARID1A-mutated Endometrial Cancer Avelumab, M1774 - Endometrial Cancer, ARID1A Gene Mutation | Phase 2 | Active not recruiting | Panagiotis Konstantinopoulos, MD, PhD | 8 | 2024-11-14 | 2026-10-26 |
| Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder) Avelumab, Tuvusertib - Urothelial Carcinoma | Phase 2 | Withdrawn | EMD Serono Research & Development Institute, Inc. | 2024-08-16 | 2024-09-27 | |
| Trial of INI-4001 in Patients With Advanced Solid Tumours INI-4001, Nivolumab, Pembrolizumab - Advanced Solid Tumor | Phase 1 | Completed | Inimmune Corporation | 10 | 2024-07-01 | 2026-10-16 |
| Drug Screening Using IMD in Bladder Cancer Implantable Micro-Device, Methotrexate, Carboplatin - Muscle Invasive Bladder Urothelial Carcinoma | Early Phase 1 | Enrolling by invitation | Brigham and Women's Hospital | 18 | 2024-06-14 | 2026-05-18 |
| Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) Lurbinectedin, Avelumab - Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary Tract | Phase 2 | Recruiting | National Cancer Institute (NCI) | 45 | 2024-06-13 | 2026-10-16 |
| Avelumab, Palbociclib and Axitinib in Advanced RCC Axitinib, Palbociclib, Avelumab - Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Withdrawn | Bradley A. McGregor, MD | 2024-05-31 | 2023-09-07 | |
| Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial Avelumab, Biopsy Procedure, Biospecimen Collection - Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 50 | 2024-05-21 | 2026-07-31 |
| JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study Avelumab - Urothelial Carcinoma | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 360 | 2024-05-09 | 2026-08-11 | |
| Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Zelenectide pevedotin, Pembrolizumab, Gemcitabine + cisplatin Or carboplatin - Metastatic Urothelial Cancer | Phase 2 | Active not recruiting | BicycleTx Limited | 375 | 2024-01-24 | 2026-10-29 |
| A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer Avelumab, Aspirin, Lansoprazole - Breast Cancer | Phase 2 | Withdrawn | The Christie NHS Foundation Trust | 2023-12-01 | 2025-12-08 | |
| Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI CP-506, Carboplatin, Immune checkpoint inhibitor - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Recruiting | Maastricht University Medical Center | 126 | 2023-05-30 | 2025-10-07 |
| Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin - Metastatic Cancer, Urothelial Carcinoma | Phase 2 | Withdrawn | AdventHealth | 2023-05-08 | 2024-08-01 | |
| Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 TILT-123, Avelumab - Melanoma, Head and Neck Squamous Cell Carcinoma | Phase 1 | Active not recruiting | TILT Biotherapeutics Ltd. | 15 | 2023-03-08 | 2026-10-13 |
Showing 20 of 269. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (29) · Carcinoma, Transitional Cell (29) · Urinary Bladder Neoplasms (26) · Carcinoma, Renal Cell (22) · Neoplasms (22) · Carcinoma, Merkel Cell (21) · Neoplasm Metastasis (18) · Breast Neoplasms (16) · Colorectal Neoplasms (16) · Squamous Cell Carcinoma of Head and Neck (15) · Ovarian Neoplasms (14) · Triple Negative Breast Neoplasms (11) · Melanoma (9) · Pancreatic Neoplasms (9) · Head and Neck Neoplasms (8)
Pfizer (26) · ImmunityBio, Inc. (23) · EMD Serono Research & Development Institute, Inc. (15) · National Cancer Institute (NCI) (11) · M.D. Anderson Cancer Center (7) · Gruppo Oncologico del Nord-Ovest (5) · Memorial Sloan Kettering Cancer Center (5) · Dana-Farber Cancer Institute (4) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (4) · Merck KGaA, Darmstadt, Germany (4) · Fred Hutchinson Cancer Center (3) · Royal Marsden NHS Foundation Trust (3) · Samsung Medical Center (3) · Universitair Ziekenhuis Brussel (3) · 4SC AG (2)
United States (154) · Italy (40) · Spain (38) · France (37) · United Kingdom (35) · South Korea (33) · Australia (31) · Belgium (29) · Canada (29) · Germany (26) · Japan (21) · Hungary (17) · Poland (17) · Netherlands (16) · Taiwan (14)
Anne Armstrong (2) · Kevin C Conlon, M.D. (2) · Matthias M Weber, MD (2) · Panagiotis Konstantinopoulos, MD, PhD (2) · Simron Singh (2) · Aaron Goldberg, MD, PhD (1) · Abhishek Tripathi, MD (1) · Adilia Hormigo, MD, PhD (1) · Adrienne Waks, MD, PhD (1)
PMID 31553054, PMID 32508818, PMID 32945632, PMID 33219092, PMID 33947608, PMID 35166465, PMID 35504244, PMID 37526095, PMID 19269895, PMID 27592805, PMID 28239472, PMID 29217288, PMID 29273043, PMID 29347993, PMID 29512061, PMID 29530667, PMID 29566106, PMID 29914528, PMID 30052729, PMID 30262187, PMID 30348224, PMID 30605211, PMID 30651126, PMID 30676622, PMID 30717797, PMID 30779531, PMID 31023100, PMID 31053174, PMID 31401903, PMID 31538815, PMID 31563412, PMID 31639039, PMID 31651359, PMID 32079623, PMID 32299817, PMID 32339648, PMID 32375680, PMID 32379297, PMID 32414862, PMID 32430019, PMID 32472503, PMID 32620210, PMID 32620211, PMID 32766875, PMID 32849281, PMID 32895571, PMID 32907924, PMID 32938212, PMID 33125944, PMID 33139266
2017 (13), 2018 (13), 2015 (11), 2016 (8), 2014 (4), 2019 (4), 2023 (4), P30CA015704 (3), U10CA180821 (3), 2025 (1), K24CA139052 (1), P01CA225517 (1), P30CA014089 (1), P30CA016672 (1), P30CA138292 (1)